Bridge Biotherapeutics, Inc.

KOSDAQ:A288330 Stock Report

Market Cap: ₩242.1b

Bridge Biotherapeutics Balance Sheet Health

Financial Health criteria checks 6/6

Bridge Biotherapeutics has a total shareholder equity of ₩12.5B and total debt of ₩0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are ₩21.4B and ₩8.8B respectively.

Key information

0%

Debt to equity ratio

₩0

Debt

Interest coverage ration/a
Cash₩9.14b
Equity₩12.54b
Total liabilities₩8.81b
Total assets₩21.35b

Recent financial health updates

Recent updates

Here's Why We're Not Too Worried About Bridge Biotherapeutics' (KOSDAQ:288330) Cash Burn Situation

Feb 17
Here's Why We're Not Too Worried About Bridge Biotherapeutics' (KOSDAQ:288330) Cash Burn Situation

A Look At Bridge Biotherapeutics' (KOSDAQ:288330) Share Price Returns

Dec 23
A Look At Bridge Biotherapeutics' (KOSDAQ:288330) Share Price Returns

Financial Position Analysis

Short Term Liabilities: A288330's short term assets (₩9.7B) exceed its short term liabilities (₩6.2B).

Long Term Liabilities: A288330's short term assets (₩9.7B) exceed its long term liabilities (₩2.6B).


Debt to Equity History and Analysis

Debt Level: A288330 is debt free.

Reducing Debt: A288330 currently has no debt however we can't compare to 5 years ago as we have no data for that period.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: A288330 has sufficient cash runway for 4 months based on last reported free cash flow, but has since raised additional capital.

Forecast Cash Runway: A288330 is forecast to have sufficient cash runway for 4 months based on free cash flow estimates, but has since raised additional capital.


Discover healthy companies